🚨 We are proud to announce that our co-founder Stefania Rapino will be a speaker at #WeMakeFuture24! 🧫 She will present how InSimili can revolutionize drug discovery in the Future of Health Challenge. 🚀 Come meet us at Bologna Fiere the 13th and 14th of June for WMF - We Make Future !
InSimili’s Post
More Relevant Posts
-
Are you attending Probiota 2024? I’d love to connect with you! Let’s discuss how Atlantia Clinical Trials can speed up your products Go-To-Market with robust scientific proof that holds up under scrutiny. See you in Milan! #probiota2023 #MicrobiomeResearch #ClinicalTrials #InnovationInScience
-
-
Head of Sales @ SciBite | Driving Growth and Success in Life Sciences Software Sales
Good opportunity to learn from SciBite’s Head of Ontologies, Jane Lomax, and J Christian Baber from Pistoia Alliance on the importance and application of #ontologies in the context of #genAI in the #lifesciences.
We're excited to present at Henry Stewart Events later this week. Catch our Head of Ontologies Jane Lomax as she co-presents on 'Ontologies in Pharma: The Landscape, Pre-competitive Development, and Use-Cases' with @Christian Baber, Chief Portfolio Officer, Pistoia Alliance.
-
-
How are GenAI, FAIR data, and knowledge graphs complementary? Hear from AstraZeneca's Tom Plasterer on the topic, along with experts from Pistoia Alliance, Zifo, and ONTOFORCE, by watching the recording of our recent fireside chat on FAIR data in life sciences.🔥 👉 Check out the recording: https://lnkd.in/e-Ctdh44 #fairdata #knowledgegraphs #genai Giovanni Nisato, Bérénice Wulbrecht, Aishwarya Balajee
-
Great to see this in print! Axian supported BMS (Jeremy Jokinen, Sibel Guerler) in bringing together experts in #behaviouralscience (Joanne Treacy Elaine H Morrato, DrPH MPH, Rob Horne Michael Wolf Mark Lightowler PhD, GFMD Ameet Bakhai) to explore how learnings from the field could help improve pharma #riskmanagement. Hoping that this work sparks a conversation in how we can move beyond a focus on information provision.
-
-
💡🔬 Join Marken's enlightening webinar to delve into the future of healthcare with the emergence of advanced therapeutic medicinal products (ATMPs). These groundbreaking treatments offer hope for curing debilitating diseases, but also present challenges in manufacturing and logistics. Attendees will explore: ➡️ Types of ATMPs and ongoing research diversifying targeted diseases ➡️ Evolution of regulatory frameworks to keep pace with rapid advancements ➡️ Strategies for resilience and disruption mitigation in the ATMP supply chain 🌟 REGISTER HERE: https://buff.ly/3OQMePC Featured speaker: Rohin I. #GeneTherapy #CellTherapy #ClinicalTrialLogistics #ClinicalSupplyChain #CellAndGeneTherapies
-
-
🌐 The Lynx.MD team is heading to San Diego for DIA 2024. Drug discovery is a complex, lengthy process. DIA brings together the life sciences community to discuss innovations accelerating advancements, bringing therapies to care faster. Reach out to the Lynx.MD team, including Collin Labar, on LinkedIn to learn more about how our partners are using Lynx.MD’s rich structured and unstructured data sets to find insights addressing medical affairs and market access. See you at #DIA2024! 🌟 #Data #Research
-
-
The main goal of the Access to Medicine Foundation is to influence companies to act on expanding access to the key healthcare products they produce. That includes working in partnership with other stakeholders to solve systemic problems that prevent equitable access. In this video, hear more about the tangible ways companies use our findings to advance access. If you work in the pharma industry itself, there are useful insights about how you can take our findings forward so that people globally get access to the medicines they need. Please note that this video is not intended as an endorsement of a specific company by the Foundation, or vice-versa, as we are an independent non-profit organisation.
How do #pharma companies use the Access to Medicine Foundation’s research and insights? And how does our work inform – and boost – their efforts to expand #AccesstoMedicine in low- and middle-income countries #LMICs? This new #interview sheds light on how the Foundation has impacted the companies, from showcasing best practices to providing insights that can be used to expand access. Watch the full video ➡ https://lnkd.in/epYUWdCz Learn about the impact of our work so far ➡ https://lnkd.in/ehTb8Qgz #AccesstoHealthcare #EquitableAccess #GlobalHealth #DrivingChange #MakingaDifference #changemaking #impact
Interview with Boehringer Ingelheim's Maria Lucia Tereno and Dr Ina Witte
https://www.youtube.com/
-
Looking to share data from your publication, add a #visualabstract to help it jump out of the page, that's what Antonio Pisani and colleagues did for their new publication looking at patients moving from agalsidase beta to miglastat using the #fabry registry. Their findings indicate variability in long-term outcomes after switching from ERT to migalastat, underscoring the importance of careful monitoring. Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis Antonio Pisani, Kathryn Wilson, Julie Batista, Ilkka Kantola, Alberto Ortiz, Juan Manuel Politei, Laila Al-Shaar, Manish Maski, MD, MMSc, Ana Crespo, Elvira Ponce León, and Aleš Linhart https://lnkd.in/ePYRRuTz Sanofi Fabry International Network
-
💡🔬 Join Marken's enlightening webinar to delve into the future of healthcare with the emergence of advanced therapeutic medicinal products (ATMPs). These groundbreaking treatments offer hope for curing debilitating diseases, but also present challenges in manufacturing and logistics. Attendees will explore: ➡️ Types of ATMPs and ongoing research diversifying targeted diseases ➡️ Evolution of regulatory frameworks to keep pace with rapid advancements ➡️ Strategies for resilience and disruption mitigation in the ATMP supply chain 🌟 REGISTER HERE: https://buff.ly/3OQMePC Featured speakers: Rohin I. Wayne Chester #GeneTherapy #CellTherapy #ClinicalTrialLogistics #ClinicalSupplyChain #CellAndGeneTherapies
-
-
Looking forward to connecting with experts from >40 countries and discuss opportunities and challenges in our industry. See you in #Basel at #SwissBiotechDay!
As a member of the Swiss Biotech Association, we are excited to join the many senior experts from the global life sciences industry at 🔜 #SwissBiotechDay at Basel Congress Centre next week. 📆On Monday, AZAFAROS B.V. CEO, Stefano Portolano, MD, will give a presentation during the "Clinical Stage Biotech Companies Track" session, which will take place at 🕞15:30 in the 📌 Samarkand Room. Our Head of Business Development, Giulia Vestri, Ph.D., MBA, will also join the conference to engage with investors and network with other attendees. As a clinical-stage biotech company with most of its staff based in Basel, we are really looking forward to sharing the progress of our lead asset, #nizubaglustat, with industry experts at this prestigious local event. We are making progress with our program to develop treatment options for patients with #GM1, #GM2 and Niemann-Pick Disease Type C (#NPC), and are looking forward to sharing the data of our completed RAINBOW study later this year https://lnkd.in/e5H5yzWH. #SwissBiotech, #Azafaros, #collaboration, #innovation, #biotech, #networking, #investors, #rarediseases, #GM1, #GM2, #NPC
-
